Ionis Pharmaceuticals Inc (OQ:IONS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2855 Gazelle Court
CARLSBAD CA 92010
Tel: N/A
Website: https://www.ionispharma.com
IR: See website
<
Key People
Brett P. Monia
Chief Executive Officer, Director
Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
Joseph T. Baroldi
Executive Vice President, Chief Business Officer
Richard S. Geary
Executive Vice President, Chief Development Officer
Kyle Jenne
Executive Vice President - commercial
Eugene Schneider
Executive Vice President, Chief Clinical Development Officer
Eric E. Swayze
Executive Vice President - Research
Patrick R. O'Neil
Chief Legal Officer, General Counsel and Corporate Secretary
Business Overview
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company's products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Financial Overview
For the three months ended 31 March 2024, Ionis Pharmaceuticals Inc revenues decreased 8% to $119.5M. Net loss increased 15% to $142.8M. Revenues reflect SPINRAZA royalties decrease of 23% to $38.5M. Higher net loss reflects Research and Development in COR/COGS increase of 8% to $192M (expense), Selling/General/Admin. Expense increase of 14% to $43.7M (expense), Interest expense - Balancing value increase from $8K to $4.1M (expense).
Employees: 927 as of Feb 15, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $4,721M as of Mar 31, 2024
Annual revenue (TTM): $776.62M as of Mar 31, 2024
EBITDA (TTM): -$376.27M as of Mar 31, 2024
Net annual income (TTM): -$384.77M as of Mar 31, 2024
Free cash flow (TTM): -$341.29M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 145,965,374 as of May 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.